NovaBay’s Aganocide Shows Efficacy In Pre-Clinical Infected Human Nail Model Of Onychomycosis

NovaBay has announced that its Aganocide compounds demonstrate potent antifungal activity in an established pre-clinical infected nail model of onychomycosis. The study data will be presented at the 47th annual meeting of the infectious diseases society of America (IDSA) in Philadelphia.

Behzad Khosrovi, senior vice president of product development at NovaBay said: “This model tests both the penetration of the nail as well as the effectiveness of the compounds against the targeted fungus. What is remarkable is that, after treatment, the Aganocide formulations were able to eradicate the fungi grown on the other side of the nail, hence indicating not only good penetration but a good antifungal activity against T. rubrum, the fungus responsible for onychomycosis commonly known as nail infection. Nail fungus is notoriously difficult to treat predominantly due to the inability of many topical antifungal drugs to penetrate the nail, a hurdle we were able to overcome due to the proprietary characteristics of our compounds.”

The study “In Vitro Evaluation of Stable Derivatives of the Chlorotaurines Infected Human Nail Model as Potent Antifungal Agents for the Treatment of Onychomycosis” tested formulations of both N,N-dichloro-2,2-dimethyltaurine (NVC-422) and N-chloro-2,2-dimethyltaurine (NVC-612). Both proprietary NovaBay compounds, which are stable derivatives of endogenous chlorotaurines that possess potent and rapid antimicrobial activity against a wide range of pathogens. The endogenous chlorotaurines play an important role in mammalian innate immunity to invading pathogens.

Ron Najafi, chairman and chief executive officer of NovaBay, said: “Onychomycosis represents a significant market opportunity for any topical agent. We are encouraged by these preclinical results, especially given the rigor of the MedPharm model and its established and predictive value.”